Jardiance (empagliflozin) / Eli Lilly, Lupin, Boehringer Ingelheim - LARVOL DELTA

Empagliflozin reduces liver fibrosis by restoring catechol-O-methyltransferase activity associated with magnesium levels. (PubMed, Sci Rep) - "We demonstrated that SGLT2 inhibitors regulate sympathetic activity by enhancing COMT activity in diabetic mice. These findings suggest a new potential health benefit of SGLT2 inhibitors."

Journal • Diabetes • Fibrosis • Immunology • Liver Cirrhosis • Metabolic Disorders • Type 2 Diabetes Mellitus • COMT • IL6

Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin compared to Empagliflozin. (PubMed, J Cardiovasc Pharmacol) - "This trial will provide novel mechanistic insights into the antithrombotic activity of SGLT1/2 inhibition. If confirmed, these findings may explain the additional cardiovascular protection observed with sotagliflozin and support its use in HF patients at high thrombotic risk."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Myocardial Infarction • Thrombosis

Empagliflozin in stage 4 non-diabetic kidney disease (ANZCTR) - P3/4 | N=6 | Terminated | Sponsor: University of Otago | Recruiting ➔ Terminated

Trial termination • Chronic Kidney Disease • Nephrology • Renal Disease

Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial. (PubMed, BMC Res Notes) - "ir (IRCT20191231045959N1). 2020-01-19."

Clinical • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

SGL-TX-MR: Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension (clinicaltrials.gov) - P4 | N=8 | Active, not recruiting | Sponsor: Odense University Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Metabolic Disorders • Transplantation

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Handok Inc. | Recruiting ➔ Completed

Trial completion

Euglycemic Diabetic Ketoacidosis Triggered by Sepsis in a Patient on Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor Therapy: A Case of Diagnostic and Therapeutic Challenges. (PubMed, Cureus) - "We report the case of a 69-year-old male with a history of diabetes mellitus managed with insulin, semaglutide, and empagliflozin, who presented with syncope, bradycardia, and gastrointestinal symptoms following antibiotic treatment for a lower extremity infection...Multidisciplinary management included aggressive fluid resuscitation, insulin therapy, empirical antibiotic coverage with vancomycin, and surgical debridement of a subsequently identified foot abscess...This case highlights the critical need for early recognition of EDKA in patients on SGLT2 inhibitors, particularly in sepsis. Timely diagnosis, prompt management of underlying infections, and a multidisciplinary approach are essential for favorable outcomes."

Journal • Cardiovascular • Diabetes • Infectious Disease • Metabolic Disorders • Septic Shock • Type 2 Diabetes Mellitus

SGLT2 inhibitors and acute kidney injury. (PubMed, Nephrol Dial Transplant) - "Since the introduction of the first SGLT2 inhibitor in 2012, dapagliflozin, canagliflozin and empagliflozin have been developed and been rapidly integrated into clinical medicine, initially to manage type 2 diabetes. We conclude that SGLT2i may reduce the risks for AKI in humans. We speculate on mechanisms by which SGLT2 inhibitors may protect against AKI."

Journal • Acute Kidney Injury • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study. (PubMed, Medicina (Kaunas)) - "Resistance exercises and adequate dietary protein intake should be recommended to preserve muscle mass in at-risk patients. Larger randomized trials are needed to confirm the long-term effects of SGLT2 inhibitors on body composition particularly in older adults."

Journal • Observational data • Real-world evidence • Cardiovascular • Diabetes • Metabolic Disorders • Sarcopenia • Type 2 Diabetes Mellitus

Impact of SGLT2 Inhibitors Use on Risk of Postoperative Acute Kidney Injury Following Metabolic and Bariatric Surgery: A Retrospective Study. (PubMed, Obes Surg) - "Preoperative SGLT2is use in patients undergoing MBS is associated with a reduced risk of GFR decline in those with longer-duration diabetes, suggesting potential renoprotective benefits. No increased risk of adverse outcomes was observed when these medications were discontinued ≥ 1 week before surgery."

Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • Critical care • Diabetes • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Does Glycosuria Due to SGLT2 Inhibitors Interfere with Proteinuria Measurement? (WTC 2025) - "In the presence of glycosuria, overestimating urine creatinine could lead to underestimation of urine ACR, with the potential to falsely attribute the reduction in proteinuria to the beneficial effect of SGLT2 inhibitors.In kidney recipients receiving SGLT2 inhibitors, whether the resultant glycosuria interferes with urine creatinine measurement is unknown.* We studied 69 kidney recipients: 33 on SGLT2 inhibitors (experimental group, 25 males, mean (SD) age 60 (15) years, 19 on dapagliflozin, and 14 on empagliflozin), and 36 not on SGLT2 inhibitors (control group, 20 males, mean (SD) age 60 (12) years).Urine specimens obtained during their routine clinic visits were split into two aliquots, and urine creatinine was measured using the Jaffe colorimetric assay (Siemens ADVIA XPT Chemistry System) and the enzymatic creatinine assay (Roche c501 module).We used Bland-Altman (BA) plots and the Deming regression to compare the two methods.* The median (IQR) urine glucose..."

Renal Disease

Combined Use of Empagliflozin and Liraglutide Protects Against Tacrolimus-Induced Pancreatic and Kidney Injury through Suppression of Oxidative Stress (WTC 2025) - "In conclusion, combined use of EMPA and LIRA may offer a potent therapeutic strategy for managing TAC-induced kidney and pancreatic damage."

Oxidative stress • Fibrosis • Immunology • Renal Disease

SGLT2i Treatment Modulates Tacrolimus-Mediated Nephrotoxicity (WTC 2025) - "Our findings suggest that SLGT2i may provide intrinsic renal protection in acute calcineurin inhibitor injury. Empagliflozin appears to mitigate mitochondrial dysfunction. Further studies are underway to assess in vivo effects in a CNI-nephrotoxicity model."

Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Solid Organ Transplantation • HMGB1 • IL6 • SDHB

Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Kidney Transplant Recipients with Chronic Kidney Disease with or without Diabetes (WTC 2025) - "This study aims to evaluate the renal effects of SGLT2i in KTRs with CKD with or without diabetes.* A retrospective chart review was conducted to evaluate adult KTRs with CKD with or without diabetes that were on empagliflozin or dapagliflozin therapy at an outpatient transplant clinic from February 2023 to February 2025. SGLT2i therapy demonstrated a renal protective effect in KTRs with CKD with or without diabetes as evidenced by increased eGFR and decreased proteinuria after 12 months of therapy. The majority of KTRs on SGLT2i therapy did not have UTIs; however, close monitoring for recurrent UTI in KTRs on SGLT2i is important as half of the KTRs that did experience a UTI had recurrent infection. Larger studies are warranted to further assess the renal effects of SGLT2i in KTRs with CKD with or without diabetes."

Clinical • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Transplantation

Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2is) in Kidney Transplant Recipients (WTC 2025) - "Empagliflozin was the most prescribed SGLT2i and median time from transplant to drug initiation was 731 days... SGLT2is appear to be safe for use in KTRs with low risk of UTI, AKI, or foot infections, and overall low incidence of drug discontinuation. Further studies are needed to study long-term impact of SGLT2i on allograft and patient survival."

Clinical • Acute Kidney Injury • CNS Disorders • Infectious Disease • Metabolic Disorders • Nephrology • Transplantation

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=416 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease (clinicaltrials.gov) - P3 | N=11800 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Cardiovascular • Congestive Heart Failure • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Microbes and Glomerular Filtration Rate in Health and CKD in Mice. (PubMed, J Am Soc Nephrol) - "The microbiome plays a key role in 'setting' baseline GFR by a mechanism which partially involves tubuloglomerular feedback, and, suppressing gut microbes can elevate GFR even in CKD mice."

Journal • Preclinical • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

Outcomes of empagliflozin versus dapagliflozin treatment in patients with heart failure based on left ventricular ejection fraction: a multicentre cohort study (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a systematic review (ESC-WCC 2025) - No abstract available

Clinical • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Effects of early empagliflozin in acute decompensated HFrEF on ventricular systolic and diastolic parameters: interaction with endothelial function and arterial stiffness (ESC-WCC 2025) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

Empagliflozin improves metabolic profile and prevents myocardial and coronary dysfunction in diabetic rat hearts subjected to ischemia/reperfusion injury (ESC-WCC 2025) - No abstract available

Preclinical • Cardiovascular • Reperfusion Injury

Empagliflozin preserves hemodynamics and left ventricular function in nephrectomized rats after ischemia-reperfusion injury: a potential direct cardioprotective effect of SGLT2 inhibitor (ESC-WCC 2025) - No abstract available

Preclinical • Cardiovascular • Reperfusion Injury

Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure